EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mild antecedent COVID-19 associated with symptom-specific post-acute sequelae

Tiffany A Walker iD, Alex D Truong, Aerica Summers, Adviteeya N Dixit, Felicia C Goldstein, Ihab Hajjar, Melvin R Echols iD, Matthew C Woodruff, Erica D Lee, Seema Tekwani, Kelley Carroll, Ignacio Sanz und 2 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0288391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Tiffany A Walker und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of General Internal Medicine, Emory University, Atlanta, GA, United States of America. Hauptthemen laut MEDLINE: COVID-19, Post-Acute COVID-19 Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Woodruff Health Sciences Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The impact of COVID-19 severity on development of long-term sequelae remains unclear, and symptom courses are not well defined.

Methods

This ambidirectional cohort study recruited adults with new or worsening symptoms lasting ≥3 weeks from confirmed SARS-CoV-2 infection between August 2020–December 2021. COVID-19 severity was defined as severe for those requiring hospitalization and mild for those not. Symptoms were collected using standardized questionnaires. Multivariable logistical regression estimated odds ratios (OR) and 95% confidence intervals (CI) for associations between clinical variables and symptoms.

Results

Of 332 participants enrolled, median age was 52 years (IQR 42–62), 233 (70%) were female, and 172 (52%) were African American. Antecedent COVID-19 was mild in 171 (52%) and severe in 161 (48%). In adjusted models relative to severe cases, mild COVID-19 was associated with greater odds of fatigue (OR:1.83, CI:1.01–3.31), subjective cognitive impairment (OR:2.76, CI:1.53–5.00), headaches (OR:2.15, CI:1.05–4.44), and dizziness (OR:2.41, CI:1.18–4.92). Remdesivir treatment was associated with less fatigue (OR:0.47, CI:0.26–0.86) and fewer participants scoring >1.5 SD on PROMIS Cognitive scales (OR:0.43, CI:0.20–0.92). Fatigue and subjective cognitive impairment prevalence was higher 3–6 months after COVID-19 and persisted (fatigue OR:3.29, CI:2.08–5.20; cognitive OR:2.62, CI:1.67–4.11). Headache was highest at 9–12 months (OR:5.80, CI:1.94–17.3).

Conclusions

Mild antecedent COVID-19 was associated with highly prevalent symptoms, and those treated with remdesivir developed less fatigue and cognitive impairment. Sequelae had a delayed peak, ranging 3–12 months post infection, and many did not improve over time, underscoring the importance of targeted preventative measures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Post-Acute COVID-19 SyndromeAdultFemaleHumansMaleMiddle AgedCohort StudiesDisease ProgressionFatigueHeadache

Autor:innen und Institutionen

  • Department of Medicine, Division of General Internal Medicine, Emory University, Atlanta, GA, United States of America.
  • Grady Post-COVID Clinic, Grady Memorial Hospital, Atlanta, GA, United States of America.
  • Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, United States of America.
  • Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
  • Department of Cardiology, Morehouse School of Medicine, Atlanta, Georgia, United States of America.
  • Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, United States of America.

ORCID-Profile: Tiffany A Walker, Melvin R Echols

Förderung

  • Woodruff Health Sciences Center

Zitieren

APA

Walker, T. A., Truong, A. D., Summers, A., Dixit, A. N., Goldstein, F. C., Hajjar, I., Echols, M. R., Woodruff, M. C., Lee, E. D., Tekwani, S., Carroll, K., Sanz, I., Lee, F. E., & Han, J. E. (2023). Mild antecedent COVID-19 associated with symptom-specific post-acute sequelae. PLOS ONE. https://doi.org/10.1371/journal.pone.0288391

Vancouver

Walker TA, Truong AD, Summers A, Dixit AN, Goldstein FC, Hajjar I, et al. Mild antecedent COVID-19 associated with symptom-specific post-acute sequelae. PLOS ONE. 2023. doi:10.1371/journal.pone.0288391

BibTeX
@article{Walker2023,
  author = {Walker, Tiffany A and Truong, Alex D and Summers, Aerica and Dixit, Adviteeya N and Goldstein, Felicia C and Hajjar, Ihab and Echols, Melvin R and Woodruff, Matthew C and Lee, Erica D and Tekwani, Seema and Carroll, Kelley and Sanz, Ignacio and Lee, F Eun-Hyung and Han, Jenny E},
  title = {Mild antecedent COVID-19 associated with symptom-specific post-acute sequelae},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0288391}
}
Kostenlos starten →